Rare Disease Networks Perspectives Series – Blog 4/5
The Longest Journey: How Rare Disease Networks are Transforming Patient Journeys
There is a particular kind of loneliness that comes with a rare disease diagnosis. It is not only the uncertainty of a condition that few clinicians have encountered, or the exhaustion of a care journey that rarely follows a straight line. It is also the feeling of invisibility – of existing outside the boundaries of a medical system designed, in almost every respect, for someone else.
And it begins, for most patients, not with a diagnosis but with its absence.
“We had such a hard time finding doctors who would hear us, who would spend time with us, who would treat us,” says Sharon Drennan, whose son Rob spent fifteen years without a correct diagnosis for Blue Rubber Bleb Nevus syndrome (BRBN) – a rare vascular disorder in which abnormal blood vessel growths spread through the skin and internal organs, slowly bleeding internally and leaving Rob severely anaemic and dependent on repeated blood transfusions.” Fifteen years of appointments, referrals, wrong turns, and misdiagnoses – while a treatable condition went unrecognised.
Her experience has a name. It is called the diagnostic odyssey, and understanding that term is inseparable from understanding why rare disease networks matter as much as they do.
The Scale of the Problem
The statistics are striking, but they do not fully capture what they describe. The average time from first medical contact to confirmed rare disease diagnosis is 4.3 years. For many patients, the journey is far longer – more than half report receiving at least one misdiagnosis, and each incorrect diagnosis can add years to the search for answers. In a survey across 17 European countries, 25% of rare disease patients experienced a diagnostic delay of between 5 and 30 years.
Around 70% of rare diseases begin in childhood, meaning entire families bear the burden of a journey that may consume the most critical years of a child’s development. Approximately 30% of children with rare diseases die before reaching the age of five – in many cases, before a diagnosis has even been established. The financial toll compounds the human one: avoidable costs related to diagnostic delay range from $86,000 to over $517,000 per patient.
And yet, for most of the twentieth century, this was simply accepted as an inescapable feature of life with a rare disease.
Why the Odyssey Happens
The diagnostic odyssey is not the product of negligence or indifference. It is the predictable consequence of a healthcare system built to solve common and/or acute conditions, instead encountering diseases for which it was never designed. Patients are seen by numerous specialists who each assess only the fragment of the picture visible from their particular vantage point – symptoms that, seen together, would point clearly to a single rare condition are instead interpreted in isolation.
For those who eventually do receive an accurate diagnosis, many report a strikingly consistent turning point: they were finally heard in full. Not in fragments. Not filtered through a referral letter. But listened to, from the beginning, by someone who heard the whole story at once. That detail speaks to what patients most need and most rarely receive – not more technology, but coordinated, connected expertise. The kind that rare disease networks, almost uniquely, can provide.
Finding Each Other First
Before rare disease networks became formal research infrastructure, they began as something far simpler: patients and families finding each other. Parents connecting through early internet forums. Adults with undiagnosed diseases trading notes across borders. Caregivers sharing not just medical information, but the emotional grammar of a life organised around uncertainty.
The relief of that connection is hard to overstate. As Celena Lozano, a neuroscience PhD candidate and rare disease mother, has written of the moment her son was diagnosed with PURA syndrome and she watched other parents in online communities ask the same desperate questions she was asking: “Who wouldn’t be excited about a single therapy that could alleviate some of the negative symptoms that affect our children’s quality of life – maybe even reverse them?” The longing, the hope, the search for community – these are not peripheral to the rare disease experience; they are its texture.
The European Organisation for Rare Diseases (EURORDIS) now represents over 1,000 patient organisations across more than 70 countries. The National Organization for Rare Disorders (NORD) in the United States connects hundreds of disease-specific groups. What began as mutual support evolved into something with real scientific and policy weight, driven by a growing recognition that the knowledge held within these communities was not merely emotional but scientific. Patients who had survived a diagnostic odyssey had accumulated, often without realising it, a depth of understanding that no clinician who had seen only a handful of cases could match.
For Sharon Drennan, the moment her son Rob was correctly diagnosed came not through the formal medical system, but through an online connection that led her to the right team of specialists. Within minutes of meeting Rob, they had the answer fifteen years of appointments had failed to find. “New members all react the same when they find us,” she says of the rare disease community that eventually embraced her family. “They are relieved and grateful.” That reaction – relief at being found – is one of the most consistent emotional signatures of these networks.
From Patients to Partners
Susannah Fox, who spent two decades studying patient-led communities and served as Chief Technology Officer of the U.S. Department of Health and Human Services, identified four archetypes within rare disease networks: Seekers who pursue answers when the medical system cannot provide them; Networkers who build and sustain communities; Solvers who redesign what isn’t working; and Champions who use funding, regulatory influence, or media attention to accelerate progress for others.
What makes this framework so resonant is that it gives language to something rare disease communities have always instinctively demonstrated: that diversity of engagement is a strength. A network containing all four archetypes is, in effect, a complete innovation ecosystem – one that rare disease communities built largely without institutional recognition or support.
That recognition, when it came, was transformative. The FDA’s Patient-Focused Drug Development initiative, the European Medicines Agency’s (EMA) embedding of patient representatives in its scientific committees, and the European Reference Networks’ (ERNs) principle of bringing expertise to patients – all reflect an acknowledgement that patient communities are not merely beneficiaries of research but active contributors to it. The question of what constitutes a meaningful treatment outcome is now, in the better-functioning parts of the rare disease ecosystem, answered collaboratively.
Hope, Hard-Won
For some patients and families, rare disease networks have delivered outcomes that once seemed unimaginable. Gene therapies for spinal muscular atrophy, enzyme replacement therapies for conditions like Gaucher and Fabry disease, newborn screening programmes that can now identify dozens of conditions before symptoms emerge – all owe a significant debt to the advocacy and natural history data that patient networks made possible.
“Without the patient community, we simply would not have had the data to understand the natural history of this disease well enough to design a trial,” noted Dr. Chester Whitley, a metabolic disease specialist at the University of Minnesota. “They didn’t just participate in the research. They built the foundation it stood on.”
The impact on the diagnostic odyssey itself has been measurable. Referral to an expert centre – the kind that rare disease networks connect patients to – has been shown to reduce time to diagnosis from five to six years down to just 55 days. For families who have lived through that odyssey, that number is not a statistic. It is the difference between a childhood lost and a childhood shaped by answers.
And Real Disappointments
But the story is not only one of breakthroughs. Up to 50% of rare disease patients in Europe remain undiagnosed, and for the majority of the approximately 7,000 known rare diseases, no approved treatment exists. For every family who witnessed a therapy transform a life, there are many more who participated in trials that failed, supported research that stalled, and waited for treatments that came too late.
The emotional weight of that disappointment is profound. Patient communities are asked to contribute their time, their data, their medical histories, and their advocacy energy to research processes whose outcomes are genuinely uncertain. When a promising trial is discontinued, or a therapy is approved but remains inaccessible due to cost, the sense of breach – of having given much and received little – can be devastating.
And yet, remarkably, the disappointments have not emptied the networks. The reason, expressed consistently across conditions and cultures, is purpose: the understanding that contributing to research whose benefits may arrive too late for oneself may still matter enormously for those diagnosed a decade hence. As Lozano puts it, speaking from her dual position as scientist and rare disease mother: “As a parent, I too am hopeful. As a scientist, I believe in the promise of gene therapy.” That capacity to hold both things at once – hope and hard realism – may be the defining emotional characteristic of rare disease communities.
What Networks Have Given Back
In return for what patients and caregivers contribute, rare disease networks have, at their best, offered something genuinely valuable: visibility, voice, and the knowledge that lived experience is shaping science rather than being set aside by it. Patient-reported outcome measures developed in partnership with communities now feature in regulatory submissions in ways that were unthinkable twenty years ago. Disease-specific quality-of-life tools, fatigue scales, and caregiver burden assessments have entered the clinical lexicon because patients insisted these dimensions of experience deserved to be measured.
Perhaps most importantly, rare disease networks have begun to shorten the diagnostic odyssey itself – connecting patients to specialist expertise, pooling natural history data that helps clinicians recognise patterns they would never encounter in isolation, and advocating for the genomic testing pathways that can provide answers in weeks rather than years.
The journey to diagnosis for rare disease patients remains too long. But for a growing number of conditions, it is measurably shorter than it was.
The Moral Centre
The patient and caregiver perspective is, in the end, the moral centre of rare disease networks. It is the reason they exist, the energy that sustains them, and the standard against which all their outputs should be judged.
Sharon Drennan spent fifteen years fighting to be heard before a network finally pointed her to someone who could help. Regulators have built frameworks to accommodate patient evidence. Researchers have redesigned trials around patient-centred endpoints. All of this has happened, in large part, because patients and caregivers who had survived diagnostic odysseys of their own refused to accept that the system could not do better.
For those families, the difference a network makes is not abstract. As Kate Craddock, a caregiver whose son James lives with PKU, puts it: “Feeling like we have support through our medical team and the connections we’ve made through NORD has made these conversations so much easier and has allowed us to keep them safe and healthy.” That – safety, connection, and the knowledge that you are not navigating alone – is what rare disease networks, at their best, make possible.
Understanding what they have lived through – and what they still need – is not merely background to the story of rare disease networks. It is the story.
Next in the series: The successes and challenges of rare disease networks – what has been achieved, and what remains to be done.
